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Abstract
Background: Anti interferon-beta (IFN-b) neutralizing antibodies (NAb) affect efficacy of treatment of multiple sclerosis
patients, but exactly when the detrimental effects of NAbs offset therapeutic efficacy is debated. Quantification of
intracellular pathway-specific phosphorylation by phospho-specific flow cytometry (phosphoflow) is a promising tool for
evaluation of these effects in primary immune cells from treated patients at the single-cell level.
Method: Samples for phosphoflow and gene expression changes were collected before administration of IFN-b and at four,
six, and eight hours thereafter. Patients were NAb negative (n = 3) or were NAb positive with low/medium (n = 1) or high
(n = 2) NAb titers. Levels of phosphorylation of six Stat transcription factors (pStat) in seven cell subtypes and expression
levels of 71 pathway-specific genes in whole blood were measured. The data was subjected to principal component analysis
(PCA), fifty-fifty MANOVA, ANOVA, and partial least square regression (PLSR).
Results: PCA of pStat levels clustered patients according to NAb class independently of time. PCA of gene expression data
clustered patients according to NAb class but was affected by time and treatment. In the fifty-fifty MANOVA, NAb class was
significant for both pStat levels and gene expression data. The ANOVA identified pStat1 protein in several cell subtypes as
significantly affected by NAb class. The best fitting model for NAb prediction based on PLSR included pStat1 in monocytes,
T cells, or lymphocytes and pStat3 in monocytes (r = 0.97). Gene expression data were slightly less predictive of NAb titers.
Conclusion: Based on this proof of concept study, we hypothesize that NAb effects can be monitored by evaluation of a
single biomarker, pStat1, in either monocytes or T cells by phosphoflow directly after IFN-b administration. The method will
significantly reduce cost relative to labor intensive in vitro methods and offers a patient-specific approach to NAb
evaluation.
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Introduction
Interferon-beta preparations (IFN-b) are immunogenic and
development of neutralizing antibodies (NAb) to IFN-b is a
significant cause of treatment failure in multiple sclerosis (MS)
patients [1]. As both the appearance of NAbs and the natural
course of the disease are variable and unpredictable, it has been
difficult to predict when the detrimental effects of NAbs offset
therapeutic efficacy. No biomarkers have been identified that
correlate with IFN-b efficacy and NAb development [2]. Testing
for NAbs is recommended, and several cell line based assays are
used in clinical practice to guide therapeutic decisions [2,3]. These
assays detect and quantify NAbs in sera of patients, but the
reported titers are in many cases not correlated with clinical
outcomes. Patients who develop NAbs have no obvious adverse
effects and evaluating therapy efficacy may take months to years.
The effort to implement an in vivo gene expression assay has been
hampered by the variability among patients and by the several
hundred genes known to be regulated by IFN-b [4]. Only a test
that incorporates the patient’s own characteristics of disease and
IFN-b response will reveal the effect NAbs have in individual
patients.
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Figure 1. Schematic representation of workflow. The workflow diagram shows times and type of sample collection before and after IFN-b
administration and sample processing and analysis. Concentrations of NAbs (against IFN-b) and IFN-b were measured in sera. mRNA used for gene
expression measurements was extracted from whole blood. For signaling pathway analysis by phosphoflow, immune cell subtypes were identified
and phosphorylation levels of various Stat proteins quantified in single cells. If present in sera, NAbs prevent the initiation of the IFN-b signal at the
cell surface. In the absence of NAbs IFN-b binds to its cognate receptor and forms an activated receptor complex with associated kinases that
phosphorylate Stat proteins at specific residues. The Jak/Stat pathway is the major signaling pathway activated by IFN-b.
doi:10.1371/journal.pone.0088632.g001
Table 1. Patient characteristics.
Patient Identification
number Sex Age Disease onset EDSSa
Treatment duration
(years) IFN-b preparation NAb levelsb
106 F 39 2003 0 3 IFN-b-1a s.c. High
Rebif
108 F 40 1999 1 5 IFN-b-1b s.c. High
Betaferon
109 M 45 1984 2 3 IFN-b-1b s.c. Neg.
Extavia
110 F 37 1998 2,5 1 IFN-b-1b s.c. Neg.
Extavia
111 F 44 2002 2 3 IFN-b-1a s.c. Neg.
Rebif
112 F 49 2001 4 2 IFN-b-1a s.c. Med.
Rebif
aExpanded Disability Status Scale score.
bNAb titers were measured in sera of patients by the Mx1 induction assay.
doi:10.1371/journal.pone.0088632.t001
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Figure 2. Gating hierarchy and Stats phosphorylation. (A) Gating hierarchy in whole blood.. An average of about 11,000 events were collected
for CD33+ monocytes, 4500 for CD20+ B cells, 30,000 for CD3+ T cells, 20,000 for CD3+CD4+ T cells, 7500 for CD3+CD8+ T cells, and 120,000 CD33+
granulocytes. (B) Histogram overlays of fluorescent intensities of antibody conjugated fluorochromes specific for indicated phosphorylated Stat
proteins are shown before and after IFN-b administration. Phosphorylation levels for Stat proteins are shown in CD33+ monocytes and CD3+ T cells.
Increased intensities are represented in yellow histograms.
doi:10.1371/journal.pone.0088632.g002
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Figure 3. PCA of phosphorylated Stats proteins and gene expression levels. (A) Scores and loadings are shown for the three first PCs from
the PCA of data on phosphorylation levels of Stat proteins after IFN-b administration in vivo. In the score plot patients cluster according to NAb
classes. Patients that are NAb negative are shown with blue roundels (class 1), NAb medium patients with green triangles (class 2) and NAb high
patients with red diamonds (class 3). The loading plot reveals the variables important for patient clustering. pStat1 is negatively correlated with NAb
class 3, and pStat1 and pStat4 are inversely correlated. In both score plots the patients are defined by numbers according to Table 1. p-S1 through p-
S6: phosphorylated Stats proteins; L: lymphocytes; T3: CD3+ T cells; T4: CD3+ CD4+ T cells; T8: CD3+ CD8+ T cells; B: CD20+ B cells; M: CD33+
monocytes; G: granulocytes; NK: CD94+ NK cells. (B) Scores and loadings are shown for the two first PCs from the PCA of data on gene expression
changes after IFN-b administration in vivo. Patients cluster according to NAb class. Time of sample collection confounds clustering. The variables in
the loading plot are gene names.
doi:10.1371/journal.pone.0088632.g003
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Phospho-specific flow cytometry is an ideal platform to link the
responsiveness of the IFN-b signaling pathway in primary immune
cell subtypes to the effects of NAbs in individual patients [5]. We
have previously developed an ex vivo phosphoflow assay to directly
assess the impact of NAbs in primary immune cells from a patient
[6,7]. The results clearly showed that both low and high titers of
NAbs detected in vitro significantly affected the responsiveness of
immune cell subtypes to IFN-b. The activation potential of the
transcription factor pStat1 was identified as a possible biomarker
for NAb evaluation ex vivo.
In this proof of concept study we tested whether the
phosphorylation and thereby activation of transcription factors
of the Stats family could be measured directly after in vivo IFN-b
administration in a patient and whether an inappropriate response
to IFN-b due to NAbs could be detected and quantified
immediately after treatment. We analyzed the activation of the
IFN-b/Stat signaling pathway in single immune cell subtypes in
whole blood from patients by phosphoflow before and at several
time points after IFN-b injection. To explore whether phosphor-
ylated Stat1 (pStat1) correlates with NAb effects in vivo and thus
has potential as a clinical biomarker, results from the Stat
phosphoflow assay were compared with analyses of IFN-b
inducible gene expression in whole blood, including expression
of Mx1, a previously proposed biomarker. This study shows, to our
knowledge for the first time, that a mechanistic approach to
immunogenicity evaluation is possible with phospho-specific flow
cytometry. The responsiveness of the IFN-b signaling pathway
after IFN-b administration showed that phosphorylated Stat1
highly correlated with NAb titers in MS patients.
Materials and Methods
Patients
Patient characteristics are shown in Table 1. The study was
approved by the Regional Committee for Research Ethics (REK
Vest) and written informed consent was obtained from all patients.
During the study period, three NAb negative patients, two patients
with high NAb titers and one patient with low/medium NAb titers
being treated with INF-b-1a (Rebif) or INF-b-1b (Betaferon/
Extavia) were recruited for the in vivo study. The NAb titer of each
patient was determined by the cell line based Mx1 induction assay:
NAb-negative (,20), NAb-positive low/medium (20–300), or NAb-
positive high ($300) [8]. Patients were instructed to schedule their
subsequent INF-b injection at the Department of Neurology,
Haukeland University Hospital. This approach led to a minimum
of 60 hours interval between the last injection and the injection that
was monitored. For every patient a sample was taken before the
injection (t0) to determine basal phosphorylation levels of Stat
molecules and basal gene expression levels. Data from this time point
(t0) was used to calculate induction levels. In preliminary
experiments, samples from three NAb negative patients were
evaluated for induction of Stats at time points ranging from
30 minutes to 24 hours after IFN-b injection. We determined that
time points of 4 hours (t4), 6 hours (t6), and 8 hours (t8) after injection
were optimal for measuring phosphorylation induction by phospho-
specific flow cytometry and gene expression changes by RT-qPCR.
Sera were collected at these time points and analyzed for IFN-b
concentrations. The experiment is schematically shown in Figure 1.
Figure 4. Heat maps of phosphoflow data. Heat maps indicate median fluorescent intensities (MFI) changes of phosphorylated Stat proteins in
cell subtypes. The MFI before administration of IFN-b is represented in black and increases in MFI are shown in yellow and decreases in blue. Patients
with high NAb titers can be distinguished based on their phosphorylation patterns (arrows). Patients are numbered according to Table 1. T0: prior to
IFN-b injection; T4, T6, T8: 4, 6, and 8 hours after IFN-b administration; p-S1 through p-S6: phosphorylated Stat proteins; M: CD33+ monocytes; T3:
CD3+ T cells; T4: CD3+CD4+ T cells; T8: CD3+CD8+ T cells; B: CD20+ B cells; L: lymphocytes; G: granulocytes; NK: CD94+ NK cells.
doi:10.1371/journal.pone.0088632.g004
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Single-cell quantification by flow cytometry of
phosphorylated Stats signaling molecules after in vivo
IFN-b administration
Samples taken at 4, 6, and 8 hours after IFN-b administration
were suitable for both phosphoflow and gene expression
measurements in patient blood. Whole blood was collected in
sodium-heparin tubes (Terumo Venosafe – 0545H) and immedi-
ately lysed and fixed with BD Lys/Fix solution and processed
according to manufacturer’s instructions. Washed cells were
permeabilized with ice cold 95% methanol at room temperature
for 10 min and stored at 280uC. Two hours after collection of the
last sample, all patient samples were washed three times and
stained with indicated antibodies from BD: CD3-PE (5553333),
CD4-PE-Cy7 (348809), CD8-PacificBlue (558207), CD20-PerCp-
Cy5.5 (558021), CD33-PE-Cy7 (333946), and pStat1(Y701)-
Alexa647 (612597) and pStat6 (Y641)-Alexa488 (612000), or
pStat5 (Y694)-Alexa647 (612599) and pStat3 (Y705)-Alexa488
(557814), or pStat4 (Y693)-Alexa488 (558136) and pStat3 (S727)-
Figure 5. Time-averaged phosphoflow data of Stat proteins sorted by cell type and NAb class. Visualization of ffMANOVA and ANOVA
results with pivot tables graphs. Phosphoflow data (stimMFI/unstimMFI) for every patient for every cell subtype was averaged for time points t4, t6,
and t8. The main factor, time of sample collection, did not affect the phosphoflow data significantly. The importance of pStat1 and pStat4 in NAb class
identification are clearly visible. M: CD33+ monocytes; T3: CD3+ T cells; T4: CD3+CD4+ T cells; T8: CD3+CD8+ T cells; B: CD20+ B cells; L: lymphocytes, NK:
CD94+ NK cells. Granulocytes are not shown. MFI: median fluorescent intensity.
doi:10.1371/journal.pone.0088632.g005
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Alexa647 (558099). CD94-PE (555889) was used in combination
with all pStat antibodies in a separate tube. All antibodies were
titrated for optimal separation and staining. Cells for every
staining cocktail were obtained from an average of 200 ml whole
blood. Samples were run on the BD Canto. BD Cytometry Setup
and Tracking beads were used for standardization of application
setup and BD compensation beads were used for electronic
compensation. Compensation was evaluated by single and double
stains for optimal compensation parameters. As positive controls
and to assess whole blood phosphoflow in vivo, whole blood was re-
stimulated ex-vivo with INF-b at a high dose for maximal
phosphorylation response. In set-up experiments we determined
the dose-response curve for the ex vivo re-stimulation response with
INF-b (Avonex) in whole blood. In patients treated with INF-b-1b
(Rebif) the dose-response curve ranging from 250–5000 IU/ml
was analyzed.
Eight immune cell subtypes analyzed were identified and gated
as shown in Figure 2A, and an average of about 40,000 events
were collected on the lymphocyte gate. Heat maps and histogram
overlays were done in Cytobank software (www.cytobank.org). To
display negative fluorescent intensity measurements after com-
pensation, the inverse hyperbolic sine with a cofactor was used as
recommended by Cytobank. The signal induction for IFN-b was
calculated as the fold change of median fluorescent intensity (MFI)
of phospho-Stat protein before injection of IFN-b in specific cell
subtypes compared to MFI of samples at 4, 6, and 8 hours after
administration of IFN-b in the same cell type (Figure 2B). Relative
MFI calculations (MFI(t0)/MFI(t4,6,8)) were the bases for multivar-
iate analysis.
Gene expression changes in whole blood after in vivo
IFN-b administration
The SABiosciences kit RT2 Profiler PCR array ‘‘Human
Interferon a, b Response’’ (PAHS-016A) was used to measure
pathway-specific gene induction after IFN-b administration in vivo.
Blood was drawn directly into Tempus RNA Blood tubes from
Invitrogen (4342792) and was stored at 280uC. The blood was
processed for RNA extraction with the Spin RNA isolation kit
(Applied Biosystems, 4380204). For every plate, 500 ng RNA was
used for reverse transcription with SABiosciences RT2 First strand
kit (30401). The instrument-specific Sybr green master mix from
SABiosciences (330522) was used for amplification detection, and
gene induction was calculated by the DDCt method with
SABiosciences web-based PCR array analysis tool. Every plate
was checked for melting curves, DNA contamination, RNA
transcription efficiency, and a positive PCR control and was
passed if the values were within recommended range. The average
of the five included housekeeping genes was used for normaliza-
tion of data. The changes relative to levels before IFN-b
administration were calculated to determine gene induction.
IFN-b concentration in sera after in vivo IFN-b
administration
The VeriKine_HS Human IFN-b Serum ELISA kit (PBL
interferon source 41415-1) was used to measure levels of INF-b
before IFN-b administration and at 4, 6, and 8 hours after
injection. All samples were run on the same plate and
concentrations were calculated according to the manufacturer’s
instructions.
Data exploration, dimension reduction, and modeling
Whole data-sets were obtained for patients treated subcutane-
ously (s.c.) with IFN-b 1b (ExtaviaH/BetaferonH) or IFN-b 1a
(RebifH) of different NAb classes (negative, low/medium, and
high), eight cell subtypes, six Stat phospho-proteins, and 71 genes.
This set of data was used in further analysis of NAb effects.
Phosphoflow values for CD20+ B cells from patient 106 were
missing for technical reasons. Raw patient data will be made
available to interested parties upon receipt of a formal request and
a statement ensuring patient privacy to the Department of
Neurology, Haukeland Hospital.
PCA, an unsupervised method for scaling multi-dimensional
data sets, was used to explore and visualize the data. PCA is based
on linear transformation of the variables to principal components
(PCs) so that they can be viewed and analyzed in lower
dimensional spaces with minimal possible loss of information
about the variables and their correlations. PCA was performed
using the algorithm NIPALS in Unscrambler software (CAMO).
Missing values for patient 106 CD20+ B cells were imputed into
the iterative estimation of the scores and the loadings allowing all
data to be included. The data were mean centered and run
without scaling to unit variance.
Table 2. Fifty-fifty MANOVA of Stats phosphorylation
induction levels after IFN-b administration.
Factors Df exVarSS nPC nBU exVarPC exVarBU p-Value
Treatment 1 0.05513 2 2 0.7247 0.8976 0.0452*
Time 1 0.02792 2 2 0.7164 0.8857 0.7192
NAb class 2 0.35313 2 2 0.6978 0.8983 1.19e-7***
Trt6Time 1 0.02801 2 2 0.7509 0.9181 0.6453
Trt6NAb
class
1 0.07146 2 2 0.6886 0.9213 0.0510
Time6NAb
class
2 0.07493 2 2 0.7432 0.9214 0.3821
Residuals 9 0.34890
Significant codes: 0 ‘***’; 0.001 ‘**’; 0.01 ‘*’; 0.05 ‘.’.
The ffMANOVA of Stats proteins included 18 objects and 42 responses. Trt:
treatment; Df: degrees of freedom; exVarSS: explained variance sum of squares;
nPC: number of principal components; nBU: number of buffer components;
exVarPC: explained variance in principal components; exVarBU: explained
variance in buffer components.
doi:10.1371/journal.pone.0088632.t002
Table 3. Fifty-fifty MANOVA of gene expression induction
levels after IFN-b administration.
Factors Df exVarSS nPC nBU exVarPC exVarBU p-Value
Treatment 1 0.07779 2 2 0.7067 0.8677 0.004006**
Time 1 0.06024 2 2 0.6414 0.8457 0.000792***
NAb class 2 0.51660 2 2 0.8925 0.9521 3.34e-06***
Trt6Time 1 0.03063 2 2 0.6110 0.8368 0.059050.
Trt6NAb class 1 0.07793 2 2 0.6820 0.8673 0.002589**
Time6NAb
class
2 0.05970 2 2 0.6251 0.8365 0.007396**
Residuals 9 0.27776
Significant codes: 0 ‘***’; 0.001 ‘**’; 0.01 ‘*’; 0.05 ‘.’ The ffMANOVA of the analysis
of gene expression included 18 objects and 70 genes. Trt: treatment; Df:
degrees of freedom; exVarSS: explained variance sum of squares; nPC: number
of principal components; nBU: number of buffer components; exVarPC:
explained variance in principal components; exVarBU: explained variance in
buffer components.
doi:10.1371/journal.pone.0088632.t003
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Classical multivariate analysis of variance (MANOVA) cannot
be used when the number of responses exceeds the number of
observations or when responses are multivariate correlated. An
alternative analysis, fifty-fifty MANOVA (ffMANOVA) was
developed by Langsrud et al. as a generalization of ANOVA to
multivariate data. The test performs a simultaneous test of several
PCs [9]. The ffMANOVA was performed in the R software (www.
r-project.org). The model used included treatment, NAb class,
time, and all two-way interactions between these factors as design
variables and Stat protein phosphorylation inductions or gene
expression changes as responses. ffMANOVA performs PCA
where one design factor at the time is considered. A simultaneous
test of several principal components (PCs) is performed where the
components accounting for 50% of the variation is included in the
model, 50% of the remaining model is used for buffer, and the rest
is used for validation.
To identify significant proteins and genes, we performed both a
univariate test by ANOVA where p-values were adjusted for
multiple comparison by False Discovery Rate (FDR) using rotation
test and by multivariate analysis using jackknife modified to
bilinear data analysis as a test of the stability of the regression
coefficients upon cross validation in PLS regression [10]. The
ANOVA model was performed as described for the ffMANOVA
analysis (NAb classes, the treatments, the one and all two-way
interactions were the design parameters and the protein compo-
sition the response). To predict NAb titers, the PLS regression was
performed reversed using the proteins or the genes as regressor
variables and the NAb titers as response. The model was first
performed using all proteins or all genes as input, and thereafter
using the minimum of selected proteins or genes found significant
in the ANOVA and PLS regression. The variables were not
weighted.
For the prediction of NAb class based on protein data we tested
several PLS regression models with subsets of Stat protein data.
We were interested in the question of whether the phosphoflow
data is predictive of NAb titer. As phospho-specific flow cytometry
is costly we sought to identify the Stat protein or subset of Stat
proteins that gave the best possible prediction of responses. PLS
regression belongs to the same family of bilinear methods as PCA,
but the method is supervised and based on maximizing the
covariance between two sets of data or matrixes in order to find
latent variables in one of the matrixes that best represents and
predicts variables in the other matrix. The PLS regression was
performed using mean-centering without any weighting of
variables. The cross validation of these models was done on all
data by leaving all measurements of samples from one patient at a
time out of the analysis and using this left out sample for
validation.
Results
Stat phosphorylation patterns distinguish patients in
NAb classes
In this study, samples were collected from MS patients before
IFN-b administration and at 4, 6, and 8 hours thereafter. Levels of
NAbs, levels of IFN-b, phosphorylation levels of Stat proteins in
immune cell subtypes, and gene expression levels in whole blood
were determined (Figure 1). The eight cell subtypes analyzed were
identified and gated as shown in Figure 2A. The phosphorylation
induction of Stat proteins post-injection is shown in Figure 2B.
The unsupervised explorative multivariate analysis PCA of
protein phosphorylation and gene expression revealed that the
main variability in the protein phosphoflow data was related to
NAb class as the NAb classes could clearly be distinguished by the
three first and most important PCs in the score plot (Figure 3A and
Table 4. ANOVA of pStat protein data where all proteins significant for at least one factor are presented.
Cell-type pStat Treatment Time NAb class Trt6time Trt6NAb class Time6NAb class
CD33+ Monocytes pS1 0.725 0.065 0.000* 0.971 0.142 0.639
CD3+ T cells pS1 0.006* 0.755 0.000* 0.771 0.017* 0.554
CD3+ CD4+ T cells pS1 0.008* 0.982 0.000* 0.771 0.020* 0.504
CD3+ CD8+ T cells pS1 0.004* 0.742 0.000* 0.771 0.017* 0.645
Lymphocytes pS1 0.008* 0.359 0.000* 0.881 0.017* 0.504
CD94+ NK cells pS1 0.020* 0.151 0.000* 0.950 0.173 0.825
*Significant codes: ,0.050.
doi:10.1371/journal.pone.0088632.t004
Table 5. Averaged time points for pStat1 values for the three NAb classes.
pStats1 proteins in cell subtypesa NAb class 1 negative NAb class 2 low NAb class 3 high
CD33+ Monocytes 0.36 0.32 0.00
CD3+ T cells 0.35 0.42 0.07
CD3+ CD4+ T cells 0.35 0.43 0.07
CD3+ CD8+ T cells 0.33 0.40 0.07
Lymphocytes 0.33 0.36 0.08
CD94+ NK cells 0.43 0.42 0.07
aPhosphorylation levels of pStats1 are time averaged.
doi:10.1371/journal.pone.0088632.t005
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B). In this study, patients clustered according to NAb class
independently of time of sample collection. The three first PCs
described 74% of the total variability in the phosphoflow data.
The first two PCs accounted for 59% of the total variability and
distinguished patients that were NAb negative (NAb class 1) from
patients that were NAb high (NAb class 3), whereas the third PC
was necessary to distinguish the patient that was NAb low/
medium (NAb class 2). Phosphorylated pStat1 and pStat4 were
inversely correlated and, together with serine phosphorylation of
Stat3 (pStatS3), were the variables that contributed the most to the
clustering of patients by NAb class. No outliers were detected in
the PCA.
In the scores plot, patients in NAb class 1 clustered on the upper
left side of the plot (blue circle) and patients in NAb class 3
clustered on the right side of the plot (red circle). In the
corresponding loading plot, pStat1 variables clustered on the left
side (yellow circle) and pStat4 variables clustered on the right side
(pink circle) (Figure 3A). The location and clustering of samples
and variables in these plots showed that most of the cell subtypes in
which phosphorylation of Stat1 was measured were negatively
correlated with NAb class 3 and positively correlated with NAb
class 1. In granulocytes phosphorylation of Stat1 was located near
the origin (not included in the yellow circle) and therefore had no
Table 6. ANOVA of gene data where all genes significant for at least one factor are presented.
Gene name Treatment Time NAb class Trt6Time Trt6NAb class 6NAb class
ADAR 0.032* 0.843 0.005* 0.337 0.298 0.521
ARL5B 0.261 0.480 0.005* 0.096 0.481 0.731
ATF5 0.377 0.059 0.003* 0.115 0.759 0.273
BAG3 0.779 0.964 0.048* 0.182 0.757 0.752
BST2 0.547 0.225 0.041* 0.119 0.641 0.521
CASP1 0.036* 0.055 0.015* 0.096 0.356 0.752
CDKN1B 0.044* 0.820 0.793 0.461 0.641 0.921
CNP 0.002* 0.731 0.000* 0.047* 0.834 0.273
EIF2AK2 0.031* 0.625 0.005* 0.096 0.248 0.487
GBP1 0.001* 0.004* 0.000* 0.461 0.641 0.273
GCH1 0.032* 0.292 0.003* 0.385 0.622 0.816
HLA_DOA 0.048* 0.335 0.336 0.156 0.641 0.723
HLA_DQA1 0.558 0.501 0.041* 0.273 0.615 0.521
HLA_F 0.008* 0.225 0.036* 0.260 0.896 1.000
HLA_G 0.405 0.466 0.048* 0.973 0.645 0.902
IFI16 0.005* 0.181 0.000* 0.047* 0.298 0.816
IFI27 0.024* 0.055 0.412 0.973 0.330 0.816
IFI6 0.044* 0.004* 0.000* 0.182 0.080 0.273
IFIH1 0.065 0.507 0.000* 0.337 0.084 0.731
IFIT1 0.410 0.068 0.000* 0.808 0.307 0.273
IFIT3 0.048* 0.650 0.000* 0.260 0.084 0.816
IFITM2 0.004* 0.035* 0.002* 0.461 0.946 0.816
IFNAR2 0.009* 0.869 0.913 0.973 0.641 0.746
IRF1 0.024* 0.501 0.015* 0.461 0.977 0.731
IRF2 0.041* 0.549 0.019* 0.280 0.641 0.816
IRF7 0.010* 0.702 0.015* 0.125 0.387 0.411
IRF9 0.005* 0.564 0.009* 0.521 0.697 0.521
ISG15 0.581 0.181 0.000* 0.096 0.006* 0.430
ISG20 0.034 0.160 0.004* 0.096 0.918 0.723
MAL 0.009 0.977 0.784 0.193 0.641 0.273
MX1 0.276 0.323 0.000* 0.096 0.006* 0.521
MX2 0.622 0.225 0.000* 0.096 0.006* 0.521
MYD88 0.031* 0.731 0.015* 0.115 0.834 0.815
NPEPPS 0.024* 0.869 0.729 0.096 0.298 0.997
OAS2 0.051 0.486 0.004* 0.260 0.558 0.487
PML 0.034* 0.708 0.014* 0.521 0.760 0.816
PSME2 0.268 0.004* 0.048* 0.157 0.641 0.816
*Significant codes: ,0.050.
doi:10.1371/journal.pone.0088632.t006
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relation to NAb class. All cell subtypes for phosphorylation of Stat4
data clustered and were negatively related to NAb class 1.
The relative changes in MFIs for phosphorylated Stat proteins
after IFN-b injection are shown in heat maps in Figure 4. A
relatively small (maximum 1.7 fold), but consistent, increase in
phosphorylated Stat1 protein was observed between 4 and 8 hours
after IFN-b administration in NAb-negative patients (patients 109,
110, 111). In NAb-positive patients with high titers, levels of
phosphorylated Stat1 were clearly decreased compared to the
levels in NAb-negative patients (106, 108) (Figure 4). Fold changes
in MFIs of phosphorylated Stat proteins did not differ significantly
at 4, 6, and 8 hours relative to t0 nor was there an interaction
between the time and NAb class (Tables 2). For visualization
purpose we therefore used time-averaged fold changes in
phosphorylation levels for all Stat proteins and plotted these
against NAb class in each cell subtype in Figure 5; these graphs
illustrate the importance of pStat1 and pStat4 for the separation of
NAb classes.
Gene expression patterns after in vivo IFN-b
administration are heterogeneous
As expected, induction of expression of a number of genes was
observed after IFN-b injection. The expression values measured
are an average of whole blood mRNA. In phosphoflow, the cell
subtypes can be identified and signal induction quantified without
first separating the cells. To reduce the dimension and visualize
gene induction we used PCA on the DDCt values, which are gene
expression changes relative to gene expression levels before IFN-b
administration. Among the genes evaluated, CXCL10 had a very
high standard deviation and dominated the first PC in the PCA. A
meaningful PCA was therefore obtained by down-weighting the
data for CXCL10 in the analysis (Figure 3B). The first two PCs
explained 83% of the variance. Many genes contribute to the
clustering according to NAb class, including Mx1.
Markers predictive of NAb class
NAb class was significantly correlated with both Stat phosphor-
ylation patterns and gene expression patterns after IFN-b
administration in vivo. The significances of the PCs as analyzed
by the ffMANOVA are given in Table 2 and 3 for proteins and
genes, respectively. Results are presented using unscaled variables
for both the Stats phosphorylation data and the gene expression
changes. Two PCs were included in the model of the ffMANOVA
(nPC) and two PCs were used for buffer (nBU) both for the
proteins and for the genes. The main effects and the two-way
interactions were included in the model. Similar to the PCA in
Figure 3B, CXCL10 was removed from the analysis. NAb class was
highly significant for both the phosphoflow and gene expression
data. Treatment type was also significant for both the phosphoflow
data and gene expression. No significant interactions between the
main factors time post injection, NAb class, or treatment type were
found for phosphoflow data. The interaction between NAb class
and treatment type as well as the interaction between NAb class
and time post injection were significant for gene expression data.
Thus, the effect of NAb class on gene expression was affected by
both time of blood collection after IFN-b administration and by
the treatment type as shown in the ffMANOVA.
Statistical tests on the individual variables by ANOVA using p-
values adjusted for multiple comparisons by false detection rate
(FDR) performed by rotation test revealed significant differences in
NAb class for phosphorylation patterns in Stat1 in all cell subtypes
except granulocytes (Table 4, Figure 5). In T cell subpopulations,
but not in monocytes and NK cells, treatment and the interaction
between treatment and NAb class were significant. B cells were not
included in the ANOVA, because data on B cells was not available
for one patient. The mean values for NAb class 2 (low/medium) of
phosphorylation of Stat1 in these cell types were close to that of
NAb class 1 (negative) and close to zero for NAb class 3 (Table 5).
When the reversed model was performed using PLS regression,
where the Stat proteins were the input variables and the NAb
classes the response, the same Stats proteins were found to be
significant using the jackknife test as in the ANOVA test: Stat1
proteins were significant in all cell subtypes except granulocytes. In
addition, Stat3, Stat5, and Stat6 in monocytes and serine Stat3 in
T cells were also significant by jackknife in PLS regression analysis.
Table 7. Averaged time points for gene expression values for
the three NAb classes.
Genesa NAb class 1 negative NAb class 2 low NAb class 3 high
ADAR 2.17 2.19 1.21
ARL5B 1.19 1.73 1.04
ATF5 2.22 3.66 1.26
BAG3 0.97 1.63 1.00
CASP1 1.49 1.59 1.04
CD70 1.10 2.21 2.11
CNP 2.68 2.88 1.43
EIF2AK2 2.74 4.70 1.76
GBP1 3.53 4.96 1.47
GBP2 1.70 1.73 1.14
GCH1 2.57 2.79 1.24
HLA.F 1.12 1.13 0.95
HLA.G 1.56 3.52 0.86
IFI16 2.05 2.48 1.21
IFI6 3.62 5.30 2.14
IFIH1 3.57 3.90 1.37
IFIT1 8.51 11.98 2.49
IFIT3 5.98 8.83 2.43
IFITM2 1.36 1.35 0.97
IRF1 1.98 3.27 1.31
IRF2 1.55 2.44 1.14
IRF7 3.49 4.39 2.09
IRF9 1.61 1.92 1.18
ISG15 8.19 9.52 2.80
ISG20 2.18 2.64 1.27
MX1 5.26 6.30 2.38
MX2 3.35 3.51 1.55
MYD88 1.82 2.27 1.23
OAS2 3.18 5.66 1.84
PML 2.52 3.54 1.29
PSME2 1.28 1.65 1.21
SH2D1A 0.90 0.68 1.24
STAT1 3.73 7.49 1.96
STAT2 3.07 5.03 1.65
TAP1 1.42 1.70 0.99
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The predictive ability of the model including these variables was
high (r = 0.89).
A statistical test on individual genes by ANOVA using FDR
identified many genes that were significantly affected by NAbs in
whole blood after IFN-b injection. These genes are shown in
Table 6. For the genes ISG15, MX1, and MX2 there was a
significant interaction between NAb class and treatment, and for
the genes CNP and IFI16 there was a significant interaction
between treatment and time. The mean values of significant
ANOVA results for each NAb class are presented in Table 7.
Figure 6. PLS model of pStat1 in CD33+ monocytes and lymphocytes and pStatS3 lymphocytes and PLS model of pStat1 in CD33+
monocytes and CD3+ T cells. (A) PLS model for best prediction of NAb titers (NabT) is shown in the predicted versus reference plot. The predictor
variables were pStat1 in CD33+ monocytes and lymphocytes and pStatS3 in lymphocytes; the response variable was NabT. In the scores plot, 95% of
the variability in NabT is explained by 92% of the variability in the predictor variables using the first two factors. The blue circles represent samples for
the calibration setup model, and the red circles represent the validation samples obtained by full cross validation. (B) PLS of model of interest where
pStat1 in CD33+ monocytes and CD3+ T cells are used as predictors and NabT as response variables. RMSEC: root mean square error of calibration
(blue) and of validation (red), respectively; SEC: standard error of calibration and is similar to RMSEC, except it is corrected for bias which is the mean
value over all points that either lie systematically above (or below) the regression line. A value close to zero indicates a random distribution of points
about the regression line.
doi:10.1371/journal.pone.0088632.g006
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Stat1 phosphorylation predicts NAb titers after in vivo
IFN-b administration
The possible application of Stat protein phosphorylation data to
predict NAb class was evaluated using a prediction model based
on PLSR. Time of sampling was not significant for the Stat
phosphorylation data as shown in Table 2. This indicates that all
three time points were equally well suited for the prediction of
NAb class. Time of sampling was significant for gene expression
data (Table 3). The best fitting model for the phosphoflow data
included the variables pStat1 in monocytes and lymphocytes and
pStat3 (at serine) in lymphocytes. The predictability of NAb titers
was r = 0.97 (Figure 6A). Note that one patient at a time was
excluded when calibrating the model and used for validation,
which means that the NAb class on one patient is predicted based
on the model obtained on the remaining patients. The phosphor-
ylation induction of only Stat1 in two cell subtypes, namely CD33+
monocytes and CD3+ T cells or lymphocytes, was predictive of
NAb titers with an accuracy of r = 0.95 (Figure 6B). pStat1 in these
cell subtypes was negatively correlated with NAb titers. The same
PLS model for all proteins and cell subtypes had a similar
correlation coefficient (r = 0.95).
PLS models of gene expression changes were less predictive of
NAb titers than models based on Stat phosphorylation. When all
genes were included in the model none of the genes were found to
be significant by the jackknife test and the predictive value of this
model (r = 0.73) was lower than that based on Stat phosphoryla-
tion. When only significant genes from the ANOVA test were
included in the model the correlation coefficient was r = 0.89. The
best fitting model was obtained with four genes, Mx1, TNFSF10,
IFIT3, and IFIH1 (r = 0.91; Figure 7).
Phospho-protein induction patterns clearly separate NAb
classes in subcutaneously IFN-b-1a treated patients
The ffMANOVA test showed a significant difference between
patients treated with s.c. IFN-b-1a or s.c. IFN-b-1b, based on the
Stat phosphorylation data (Table 2,4). This treatment effect may
confound some of our PCA models. We therefore analyzed the
data from patients treated with the IFN-b preparation Rebif
separately. For this treatment, data on patients in all three NAb
classes were available. The PCA of the phospho-protein data
showed three distinct clusters for the patients with different NAb
classes based on the two first PCs and explained 71% of the
variation within the data (Figure 8A). pStat1, pStat4, and pStat3
(serine) were the most important variables in clustering of patients;
this was similar to the PCA of Stat data when all patient data was
included (Figure 3A).
To evaluate effects of NAb on the responsiveness of the IFN-b/
Stats signaling pathway, whole blood from the same s.c. IFN-b-1a
treated patients was re-stimulated ex vivo with a serial dilution of
IFN-b. The dose response curves are shown in heat maps in
Figure 8B. NAb titers affected the sensitivity of the pathway. The
PCA for the gene induction data of the same patients is shown in
Figure 8C. With the first two PCs no clustering of patients according
to NAb class was observed. PC1 and PC3, however, separated NAb
classes and explained 71% of the variation in the data.
Serum values
Serum levels of IFN-b increased after treatment in NAb
negative patients (Figure 9). In sera of patients, levels of IFN-b
before injection tended to be higher than in healthy controls,
which are either undetectable or very low in the range of 2–6 pg/
ml (PBL interferon source). In patients with high NAb titers the
IFN-b concentration measured in sera were very similar before
and after injection.
Serum NAb titers measured by the Mx1 induction assay were
dependent on time of sample collection (Figure 10). Only one
patient (108) had high and consistent NAb titers at every time
point before IFN-b administration and thereafter. NAb negative
patients remained NAb negative at every time point. A patient
(112) with low/medium NAb values fluctuated between negative
and positive values depending on time of sample collection.
Discussion
INF-b is one of the first-line treatment options for relapsing-
remitting MS. During therapy, up to 40% of patients develop
NAbs that may affect treatment efficacy [11,12]. In 2010 an
international consensus panel of MS experts concluded that
persistently high titers of NAbs are likely to be associated with
treatment failure [1]. However, the clinical impact of NAb titers is
controversial partly because of the lack of relevant tests that take a
patient’s constitution and disease variability into consideration.
Figure 7. PLS model for genes Mx1, TNFSF10, IFIT3, and IFIH1. PLS model for best prediction of NAb titers (NabT) is shown in the predicted
versus reference plot. The predictor variables were Mx1, TNFSF10, IFIH1, and IFIT3 expression, the response variable was NabT. In the scores plot, 87%
of the variability in NabT is explained by 96% of the variability in the predictor variables using the first factor. The blue circles represent samples for
the calibration setup model and the red circles represent the validation samples obtained by full cross validation. RMSEC: root mean square error of
calibration (blue) and of validation (red); SEC: standard error of calibration.
doi:10.1371/journal.pone.0088632.g007
pStat1 and Neutralizing Antibodies in IFN-b Therapy
PLOS ONE | www.plosone.org 12 February 2014 | Volume 9 | Issue 2 | e88632
Figure 8. IFN-b-1a (Rebif) treatment analyzed separately. (A) PCA of pStat proteins in patients treated with Rebif. NAb classes form distinct
clusters for all measurements. The most important variables are highlighted in the loading plot. (B) Heat map dose-response curves of ex vivo re-
stimulation with IFN-b in whole blood of the same patients. Patients are in different NAb classes: NAb negative (2), NAb medium (+), and NAb high
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Some patients are at risk of being treated for months to years with
limited or lost efficacy. In this proof of concept study we found that
interrogation of the IFN-b signaling pathway in single cells of
leukocyte subsets revealed cellular responses early after IFN-b
administration and demonstrated that the pattern of Stat
activation is inhibited and/or modulated in NAb positive patients
and that the determination of Stat1 phosphorylation alone is a
promising in vivo IFN-b activity biomarker.
The phosphorylation level of transcription factor Stat1 (pStat1)
correlated with NAb titers. The best model for prediction of NAb
titers after in vivo IFN-b injection was based on pStat1 in
monocytes and in CD3+ T cells. Similarly, ex vivo re-stimulation
of peripheral blood mononuclear cells (PBMCs) from patients with
IFN-b showed that pStat1 levels in monocytes and CD3+ T cells
contributed significantly to the clustering of patients according to
NAb classes [7]. Thus, ex vivo IFN-b re-stimulation data and data
obtained after in vivo IFN-b injection both indicate that pStat1 is a
promising biomarker for the accurate assessment of NAb effects in
individual patients.
Quantification of intracellular pathway-specific phosphorylation
levels better predicted NAb effects than gene expression changes as
levels of phosphorylated Stat proteins were more consistent and
less heterogeneous than changes in gene expression. Gene
expression was influenced by time of sample collection and by
treatment type. We previously showed that in PBMCs from
healthy people and in PBMCs from MS patients, the INF-b/Stat
signal transduction pathway is functional when the cells are re-
stimulated ex vivo with IFN-b in media without patient sera [7]. We
consistently observed cell-type specific activation of Stat proteins in
healthy individuals and untreated MS patients, and signaling
patterns were inhibited and/or modulated in the presence of
patient sera containing NAbs. Based on this more homogeneous ex
vivo signal activation pattern in PBMCs it may not be surprising
that phosphoflow data was more robust in predicting NAb effects
than were gene expression changes after in vivo IFN-b injection.
Gene induction was measured for genes known to be involved in
the response to IFN-b in humans. Twenty-one of the 36 genes that
were significant in the ANOVA were also significant in PLSR, and
ten of these genes had a high correlation to NAb titers: ADAR,
CNP, IFIT1, IFIT3, IFI16, ISG15, Mx1, Mx2, MYD88, and
TNFSF10. All of these showed marked down regulation in patients
with high NAb levels compared to NAb negative patients. These
results support the findings by Hesse et al. that in patients who lack
Mx1 expression in whole blood after INF-b administration also
lack expression of other IFN-b-inducible genes [13]. The
differences between NAb negative patients and the patient with
low/medium NAb titers were heterogeneous and possibly affected
by the large amount of endogenous IFN-b in the patient with low/
medium NAb titer. The multi-level approach in this study
elucidates the complexity of therapy response in patients but also
shows that specific measurements within the cascade that affects
signaling responses due to therapeutic agents may be used to
interpret results and guide decisions regarding therapy.
Measuring phosphorylation levels of pathway-specific transcrip-
tion factors may be more reliable than monitoring gene expression
because the measured signals are directly linked to the activation
of the IFN-b receptor at the cell surface. Although all IFN-b
signals are initiated with receptor dimerization, mechanisms of
associated kinase activation and phosphorylation of transcription
factors, integration of this signals are complex and dependent on
many factors in time and space such as activation state of cells and
cross-talk between different signal inputs. The time frame of
sample collection (hours) may influence Stat protein levels per se
and the differences in NAb class may also be explained by
translational changes. Unphosphorylated protein measurements
(++). Unstimulated samples were used as reference samples and are shown in black. Increases in phosphorylation are shown in yellow. (C) PCA of
genes in patients treated with IFN-b-1a (Rebif). For clustering according to NAb classes based on gene expression changes PC1 vs. PC2 were not
useful. However, PC1 vs. PC3 did cluster patients according to NAb class. The first number in the identification of patients in the score plot is the
patient number according to Table 1, and the second is the time of sample collection after IFN-b injection in hours. M: CD33+ monocytes; T3: CD3+ T
cells; T4: CD3+CD4+ T cells; T8: CD3+CD8+ T cells; Cd20+ B cells; L: lymphocytes; G: granulocytes; NK: CD94+ NK cells; pS1 through pS6: pStat1 through
pStat6.
doi:10.1371/journal.pone.0088632.g008
Figure 9. IFN-b levels in sera before and after IFN-b adminis-
tration. Levels of IFN-b in sera of patient numbered according to
Table 1. Numbers in parenthesis are NAb classes (1: NAb negative; 2:
NAb medium; 3: NAb high).
doi:10.1371/journal.pone.0088632.g009
Figure 10. NAb titer levels in sera of patients after IFN-b
administration. NAb titer levels measured with the Mx1 induction
assay. Patient numbers are based on those in Table 1. Numbers in
parenthesis are NAb classes (1: NAb negative; 2: NAb medium; 3: NAb
high).
doi:10.1371/journal.pone.0088632.g010
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that could discern between direct phosphorylation and translation
changes were not included in this study.
IFN-b can induce hundreds of genes and the in vivo response to
IFN-b injection assessed in blood immune cells is heterogeneous
both in gene specificity and sensitivity. Nevertheless, some genes
were specifically regulated in response to INF-b. The myxovirus
resistant protein 1 (Mx1) gene has been proposed as an in vivo
biomarker for the responsiveness of immune cells to INF-b [13–
15]. This in vivo biomarker appears to correlate with IFN-b
responsiveness in healthy individuals and in many MS patients.
The Mx1 response in patients is heterogeneous, however, and
arbitrary cutoffs are used to evaluate NAb effects in vivo.
Interestingly, the IFN-b concentrations in sera varied signifi-
cantly between patients prior to the IFN-b injection. In some
patients the INF-b concentrations were very low, similar to those
observed in healthy people, and in other patients INF-b was
clearly present in sera before the injection. The data showed an
increase in IFN-b in sera of NAb-negative patients after INF-b
injection, but not in NAb-positive patients. The different
medication regimes, as indicated by the significant treatment
effect, may explain the accumulation of IFN-b in sera of some
patients but other factors may influence IFN-b concentration as
well. Some of the components affecting the in vivo measurements in
patients may be the endogenous activation of the IFN pathway by
viral infection, INF-b receptor concentrations at the cell surface,
and the disease itself. High amounts of IFN-b were measured in
sera of patient 112. The levels of 400 ng/ml are in the range of
viral infection (personal communication from ELISA manufac-
turer). This patient had low/medium NAb titers and how high
endogenous IFN-b levels affect treatment is not known. We cannot
rule out that this patient clustered separately from patients with
high NAb levels because of this effect. Our data highlights the
intricacy of the in vivo response in patients and indicates that the in
vivo assay may also be valuable in detecting patients with an
abnormal response to IFN-b for other reasons than NAb.
In the in vitro Mx1 NAb assay, different NAb titers were
dependent on time after injection. As previously shown in many
studies, the time of sampling can confound measurements and
must be carefully chosen both in experimental settings and also for
routine analysis. Based on our analysis, a universal biomarker for
the overall INF-b response in MS patients remains elusive.
However, our data indicate that a single biomarker, pStat1, may
be appropriate for the evaluation of adverse NAb effects. We
showed that even very low/medium NAb titers inhibited the
responsiveness of PBMCs and immune cells in whole blood to
IFN-b re-stimulation ex vivo. Thus, levels of phosphorylated Stat1
correlated with NAb titers both, after IFN-b re-stimulation ex vivo
and after IFN-b administration in vivo.
In conclusion, measurements of pathway-specific activation
levels of signaling molecules after in vivo IFN-b injection are
possible, and phosphorylation patterns of Stat proteins are clearly
affected by NAbs. Patient variability in Stat protein phosphory-
lation was less than variability in gene expression data and was,
therefore, more reliable for NAb effect evaluation. We hypothesize
that NAb effects are detrimental to IFN-b therapy and that these
effects can be evaluated with a single biomarker pStat1. However,
the actual individual response to INF-b may require measuring a
panel of different signal transduction proteins. Further, our
findings indicate that multivariate analysis using tools such as
PCA and PLSR can be used to discern signals from noise and to
identify variables crucial to the system studied.
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